株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国における鎌状赤血球症治療市場

Sickle-cell Anemia Therapeutics Market in the US 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 322845
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
米国における鎌状赤血球症治療市場 Sickle-cell Anemia Therapeutics Market in the US 2015-2019
出版日: 2015年01月07日 ページ情報: 英文 51 Pages
概要

米国における鎌状赤血球症治療は、2014年から2019年の間、17.10%の複合年間成長率(CAGR)で拡大することが見込まれています。

当レポートでは、米国における鎌状赤血球症治療市場の現況と今後の見通し、市場規模とその予測、市場の成長因子と課題、主要企業の分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 疾患の概要

第6章 イントロダクション

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 購入基準

第9章 市場成長因子

第10章 成長因子とその影響

第11章 市場の課題

第12章 成長因子と課題の影響

第13章 市場動向

第14章 動向とその影響

第15章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • パイプライン分析
  • 市場シェア分析

第16章 将来有望なベンダー

第17章 主要ベンダーの分析

  • Bristol-Myers Squibb

第18章 関連レポート

目次
Product Code: IRTNTR5130

About Sickle-cell Anemia

Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.

TechNavio's analysts forecast the Sickle-cell Anemia Therapeutics market in the US to grow at a CAGR of 17.10 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Sickle-cell Anemia Therapeutics market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of the US FDA-approved drugs used for the treatment of sickle-cell anemia.

TechNavio's report, Sickle-cell Anemia Therapeutics Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the Sickle-cell Anemia Therapeutics market landscape in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Bristol-Myers Squibb
  • Future Prominent Vendors
  • Baxter
  • Bluebird Bio
  • Daiichi Sankyo
  • Eli Lilly
  • Emmaus Medical
  • GlycoMimetics
  • HemaQuest Pharmaceuticals
  • Mast Therapeutics
  • Merck Sharp & Dohme
  • Pfizer
  • Selexys Pharmaceuticals

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Side Effects Associated with Current Therapies
  • For a full, detailed list, view our report

Market Trend

  • Increased Focus on Adult Patients
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offering

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape

  • 15.1. Competitive Scenario
    • 15.1.1. Key News
    • 15.1.2. Mergers and Acquisitions
  • 15.2. Pipeline Analysis
  • 15.3. Market Share Analysis 2014

16. Future Prominent Vendors

17. Key Vendor Analysis

  • 17.1. Bristol-Myers Squibb
    • 17.1.1. Key Facts
    • 17.1.2. Business Overview
    • 17.1.3. Key Product Offerings
    • 17.1.4. Revenue by Geography
    • 17.1.5. Business Strategy
    • 17.1.6. Key Information
    • 17.1.7. SWOT Analysis

18. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Product Offering for Sickle-cell Anemia Therapeutics Market in US
  • Exhibit 2: Market Research Methodology
  • Exhibit 3: Normal erythrocytes and Sickle-shaped Erythrocytes
  • Exhibit 4: Impact of Sickled Erythrocytes on Blood Flow
  • Exhibit 5: Structure of Hemoglobin
  • Exhibit 6: Genetic Basis of Sickle-cell Anemia
  • Exhibit 7: Global Distribution of Sickle-cell Gene
  • Exhibit 8: Symptoms of Sickle-cell Disease
  • Exhibit 9: Inheritance Pattern of Sickle-cell Anemia
  • Exhibit 10: Blood Sample of Sickle-cell Disease Patients Before and After Stem Cell Transplantation
  • Exhibit 11: Laboratory Tests Recommended Before Initiation of Hydroxyurea Therapy
  • Exhibit 12: Facts for Hemoglobin Disorders
  • Exhibit 13: RuSH Project Sites
  • Exhibit 14: PHRESH: Primary Focus
  • Exhibit 15: Sickle-cell Anemia Therapeutics Market in US 2014-2019 (US$ million)
  • Exhibit 16: Life Expectancy of Sickle-cell Disease Patients in US
  • Exhibit 17: Sickle-cell Disease Treatment Demonstration Program Regional Collaborative Technical Assistance: Aims of Funding
  • Exhibit 18: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 19: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Back to Top